Completed PHASE1 INTERVENTIONAL 2-arm NCT06719986

Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg

A Study to Characterize the Time Course of Reversal of Opioid (Fentanyl)-Induced Respiratory Depression Following Administration of Nalmefene Autoinjector 1.5 mg (0.94% MgCl2) Intramuscular and Narcan® 4 mg Intranasal in Healthy Subjects

Sponsor: Purdue Pharma LP

Conditions Opioid Overdose

Interventions Nalmefene HCl injection Naloxone HCl intranasal

Updated 2 times since 2025 Last updated: Jun 16, 2025 Started: Oct 3, 2022 Primary completion: Dec 23, 2022 Completion: Dec 23, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Opioid Overdose, this trial is completed. The trial is conducted by Purdue Pharma LP and has accumulated 2 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

2 versions recorded

Aug 2025 — Present [monthly]

Completed PHASE1
Jan 2025 — Aug 2025 [monthly]

Completed PHASE1

First recorded

Oct 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Purdue Pharma LP

Data source: Purdue Pharma LP

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Columbus, United States